ethyl (E)-3-(3-fluoro-4-methoxyphenyl)acrylate | 187872-44-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (E)-3-(3-fluoro-4-methoxyphenyl)acrylate
• 英文别名: ethyl (E)-3-(3-fluoro-4-methoxyphenyl)prop-2-enoate
• CAS: 187872-44-2
• 化学式: C₁₂H₁₃FO₃
• 分子量: 224.232
• InChiKey: BWWRXUXZXLJKRC-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (E)-3-(3-fluoro-4-methoxyphenyl)acrylate 在 diethylzinc 、 二异丁基氢化铝 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 生成 [2-(3-fluoro-4-methoxyphenyl)cyclopropyl]acetaldehyde
  参考文献：
  名称：

  Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization

  摘要：

  The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.020
• 作为产物：
  描述：

  4-溴-2-氟苯甲醚 、 丙烯酸乙酯 在 palladium diacetate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 乙腈 为溶剂， 生成 ethyl (E)-3-(3-fluoro-4-methoxyphenyl)acrylate
  参考文献：
  名称：

  [EN] PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS
  [FR] DÉRIVÉS DE PYRROLOPYRAZINE À UTILISER EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V

  摘要：

  该披露涉及公式I的化合物：公式I抑制αv含有的整合素，并包括包含这些化合物的制药组合物以及用于治疗与αV含有的整合素失调相关的疾病、紊乱或状况的方法，例如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。

  公开号：

  WO2019094319A1

文献信息

• Benzocycloalkene compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05922771A1

  公开（公告）日：1999-07-13

  A compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 independently represent H or an optionally substituted hydrocarbon group; R.sup.3 represents an optionally substituted hydrocarbon group; R.sup.4 represents H or a hydrocarbon group; ring A represents a substituted benzene ring; X represents a C.sub.2-4 alkylene group etc.; and Y represents a bond or a lower alkylene group, or salts thereof is useful as prophylactic or therapeutic agents of diseases related with melatonin activity.

  式##STR1##中的化合物，其中R.sup.1和R.sup.2分别代表H或一个可选择取代的碳氢基团；R.sup.3代表一个可选择取代的碳氢基团；R.sup.4代表H或一个碳氢基团；环A代表一个取代的苯环；X代表一个C.sub.2-4烷基基团等；Y代表键或一个较低的烷基基团，或其盐，可用作与褪黑激素活性相关的疾病的预防或治疗剂。
• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• Substituted phenylalkanoic acid derivatives and use thereof
  申请人：——

  公开号：US20040044258A1

  公开（公告）日：2004-03-04

  A compound represented by the formula (I) or a salt thereof: 1 wherein n represents an integer of 1 to 3, R represents an alkyl group having 3 to 8 carbon atoms, a group represented by the following formula: R 1 (CH 2 ) k — (wherein k represents 0 or an integer of 1 to 3; R 1 represents a saturated cyclic alkyl group having 3 to 7 carbon atoms or a saturated condensed cyclic alkyl group having 6 to 8 carbon atoms, and the group R 1 may be substituted with a lower alkyl group having 1 to 4 carbon atoms) and the like, and Ar represents a condensed bicyclic group such as naphthalen-1-yl group, which has suppressing action on prostaglandin and leukotriene production and is useful for prophylactic and/or therapeutic treatment of various inflammatory diseases and the like caused by these lipid mediators.

  化合物的化学式为（I）或其盐： 其中n表示1到3的整数，R表示具有3到8个碳原子的烷基基团，由以下化学式表示的基团：R1(CH2)k—（其中k表示0或1到3的整数；R1表示具有3到7个碳原子的饱和环烷基基团或具有6到8个碳原子的饱和紧凑环烷基基团，基团R1可以被具有1到4个碳原子的较低烷基基团取代）等，Ar表示如萘-1-基团等的紧凑双环基团，具有对前列腺素和白三烯生成的抑制作用，对由这些脂质介质引起的各种炎症性疾病等的预防和/或治疗治疗有用。
• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2011159297A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。